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Adverse events in these severely ill patients were defined as those possibly/probably related to their treatment 148 (haematological, gastrointestinal and skin disorders). All other adverse events (e.g. new neurological events and 149 respiratory failure) were not incorporated in the assessment of safety and tolerability.
150
The classification and grading of adverse events was based on the Common Terminology Criteria for Adverse 151 Event (CTCAE version 4.03). Treatment was stopped in patients who had grade 4 adverse events.
153
Efficacy was assessed by mortality and clinical and neurological responses on days 3, 7, 30, 60 and 180. New 154 neurological events were defined as the occurrence of any of the following: cranial nerve palsy, motor deficits, 155 or seizures. Modified Rankin Scale (MRS) and Glasgow Outcome Scale (GOS) were used to evaluate the 156 clinical and neurological outcomes.
157
After discharge, survival was monitored by phone calls or home visits for patients who could not be reached via 158 phone. Verbal autopsies were performed via phone calls and no post-mortem autopsy was done. Based on a previous clinical trial, the number of participants needed per study arm to estimate the total exposure 162 to rifampicin (AUC 0-24h ) at a dose of 20 mg/kg, using 95% confidence and a margin of error of 20%, was n=18 163 for days 2±1 and n=16 at day 10±1.(11) Considering dropouts, 20 patients were needed for each study arm. This 164 number of participants was also shown to be sufficient to demonstrate a significant difference in AUC 0-24h 165 achieved after 10, 20 and 30 mg/kg of rifampicin.
166
Patient characteristics, rifampicin PK parameters, adverse events were presented descriptively for all patients 167 and by study group. Multiple linear regression analysis was performed to find predictors of PK parameters. The 7 number of patients with plasma AUC 0-24h and C max values above the threshold values for lower mortality of 116 169 h*mg/L and 22 mg/L at days 2±1 (as determined previously)(10) were assessed for each group. Data for 170 safety/tolerability and survival were analysed by the intention-to-treat principle. Mortality data were presented 171 as proportions in each group at various subsequent time points, and proportions were compared using the Chi- 
RESULTS

178
During the study period, out of the 229 patients with suspected TBM, 107 patients were excluded for alternative 179 diagnoses, and the remaining 122 patients were diagnosed with TBM. The 60 TBM patients who fulfilled all 180 eligibility criteria were randomly assigned to each arm (Figure 1) . Baseline characteristics are depicted in Table   181 1, showing that the patients' characteristics were equally balanced across the groups, except for fewer males in 182 the 20 mg/kg group (p=0·343) and a higher percentage of HIV positives (p=0·261) and lower CSF protein 183 concentrations (p=0·057) in the 30 mg/kg group. Overall, 53% were male, with a median age of 29·5 years, and 184 10% of patients had HIV infection.
186
Fifty-three patients had their first PK assessments (PK1) done, whereas 48 patients had a second PK evaluation 187 (PK2). Patients who failed to undergo a PK assessment were those who died or were withdrawn. The study 188 drugs were administered via a nasogastric tube (NGT) for 33 patients (62%) at the first PK assessment and for 189 nine patients (19%) at the second assessment. In some patients, their eventual plasma AUC 0-24h and C max values 190 could not be assessed reliably based on sampling at 1, 2, 4, 8 and 12 hours after the dose ( Table 2 ) and in some 191 patients concomitant CSF sampling did not take place during the two PK assessments.
193
A higher dose of oral rifampicin resulted in higher geometric mean AUC 0-24h values, i.e. three-fold higher for the 194 20 mg/kg group and five-fold higher for the 30 mg/kg group , whereas plasma C max and CSF concentrations 195 showed a more proportional increase upon increasing the rifampicin dose, both in PK1 and PK2 ( Table 2) . Large interindividual variability was observed in plasma rifampicin AUC 0-24h and C max values and in CSF 198 concentrations. For example, the differences between the minimum and maximum plasma AUC 0-24h values at 199 the first PK assessment were 9-fold for the 10 mg/kg group, 14-fold for the 20 mg/kg group, and 3-fold for the 200 30 mg/kg group (Table 2, Figure 2 ). In the multivariate analysis, the dose administered was the only predictor 201 of AUC 0-24h and C max in plasma and concentrations in CSF, whereas gender, age and BMRC grade were not 202 significant predictors (data not shown). The number of patients with drug administration via an NGT was not 203 significantly different between the three study groups and did not predict AUC 0-24h , C max or CSF concentrations 
208
Comparison of the AUC 0-24h values at the first and second PK assessment showed a significant decrease of 33% 209 at the second assessment, p=0·014 (all groups combined), with decreases of 27%, 16%, and 36% in the 10, 20 210 and 30 mg/kg groups respectively (p=0·21, 0·003, and 0·004, paired T-test on log-transformed AUC 0-24h 211 values). Similarly, CSF concentrations decreased from day 2 to day 10 of the treatment, but plasma C max values 212 did not ( Table 2) .
214
Adverse events during the 30 days after start of study drugs were equally distributed over the groups ( Table 3) .
215
The majority of adverse events was mild. Hepatotoxicity was the most common grade 3 adverse event. All 216 patients with grade 3 adverse events continued treatment and those with grade 3 hepatotoxicity had normal 217 transaminases after a median of 20 days (IQR 7·5-52) of continued treatment without interruption or dose 218 changes of rifampicin. One patient in the 30 mg/kg group had grade 4 hepatotoxicity at day 13 of treatment, as 219 reflected in hyperbilirubinemia of >10 times ULN and transaminases three times the ULN. All TB drugs were 220 interrupted, the dose of rifampicin was unblinded, and the higher rifampicin dose was replaced by a standard 221 dose. The blood total bilirubin had decreased to two times ULN, and transaminases were normalised by day 26 222 of treatment. Rifampicin AUC 0-24h and C max values in those with and without grade 3 or 4 adverse events were 223 not significantly different (p= 0·325 and 0·772).
224
The administration of higher doses of rifampicin increased the percentage of patients who achieved AUC 0-24h 225 and C max plasma threshold values for decreased mortality, as derived from our first clinical trial(9) ( Table 2) .
226
Two out of the 60 patients were withdrawn from the study on day 2, based on the clinician's consideration; one 227 9 after rifampicin resistance was identified by GenXpert ® (20 mg/kg group), and the other because of rapid 228 deterioration (30 mg/kg group) as it was considered unethical to perform multiple blood or CSF sampling in this 229 patient. Only an 'intention to treat' analysis was deemed useful for this study, as most deaths occurred before 230 the patients could complete the full 'per protocol' intervention during one month. This means that the two 231 withdrawn patients were considered to be survivors in our explorative analysis of efficacy.
232
Six-month mortality was 32% (95% Confidence Intervals (CI): 19.5%-48.1%), and the majority (12/19, 63%) of 233 deaths occurred in the first two weeks after admission. Causes of death were suspected respiratory failure (n=7), 234 septic shock (n=3), brain herniation (n=3), sudden cardiac event (n=2), pulmonary embolism (n=2) and head 235 injury (n=1). Six-month mortality was non-significantly lower in the 30 mg/kg group both among all patients 236 (p=0·12) and among the cases with definite TBM (p=0·07) ( Table 4) . Cox regression analysis showed that the 237 Hazard Ratio (HR) for administration of the triple dose versus the standard dose was 0·44 with 95% CI of 0·1-
238
1·9, p=0·27, in all TBM patients, whereas it was 0·23 (95%CI 0·03-2·05, p=0·19) among patients with definite 239 TBM (both adjusted for HIV status and GCS, see also Supplement 2).
240
New neurological events at day 3, 7, 30, 60 and 180 days, as well as functional outcome measured by MRS and 241 GOS were equally distributed among all three groups of patients (data not shown).
243
DISCUSSION
244
This study revealed that tripling the standard dose of oral rifampicin strongly increased the exposure to this 245 pivotal TB drug in plasma and CSF, did not increase the incidence of grade 3 and 4 adverse events, improved 246 the attainment of previously determined exposure threshold values for lower mortality, and showed a trend for a 247 lower six-month mortality rate among patients with microbiologically proven (definite) TBM.
248
The standard dose of rifampicin resulted in low average exposures in CSF, around the Minimum Inhibitory other tissues, and penetration to the brain is even more limited.
253
Fortunately, our intervention with higher doses of rifampicin was effective from a pharmacokinetic point of in the first critical days of treatment were higher than that of 600 mg i.v. rifampicin in our previous 259 examination(11) (170·6 and 293·5 versus 145·7h*mg/L); the average C max in the 20 mg/kg group was still 260 lower, but the 30 mg/kg group had a similar C max compared to 600 mg i.v. rifampicin (25·5 versus 24·7mg/L).
261
Our data also showed large inter-individual variability in the rifampicin exposure, which is in agreement with Adverse events after the treatment started were equally distributed among the three rifampicin dose groups. The
269
highest 30 mg/kg daily dose of rifampicin was not associated with an increase in the incidence of severe (grade 270 3 or 4) adverse events, although it should be noted that the number of patients in this phase II study was 271 relatively small. Hepatotoxicity, as reflected in ALT and AST increases, was the most common grade 3 adverse 272 event and these increases all resolved without any interruption of the study drugs. Thus, based on our data, grade 273 3 and 4 adverse events and specifically ALT and AST increases did not seem to be dependent on rifampicin 274 dose or exposure. Hepatotoxicity to rifampicin appears to be a hypersensitivity reaction, which is more common 275 with intermittent administration of larger doses.(26, 27) Studies of higher doses of rifampicin in pulmonary TB 276 also suggest that hepatotoxicity to rifampicin is idiosyncratic and not dose-related.(28, 29)
277
As to efficacy, tripling the dose of oral rifampicin for a period of 30 days led to an increase in the attainment of 278 plasma AUC 0-24h and C max thresholds for decreased mortality and highlighted a trend in survival benefit among 279 those with microbiologically proven (definite) TBM. However, this decrease in mortality was not statistically 280 significant, as our study was not designed and powered to detect a difference in mortality.
281
The overall aim of this trial was to find and substantiate the dose of rifampicin to be studied in a larger (phase 282 III) follow-up trial. We propose this dose to be 30 mg/kg orally, as this yielded the highest exposure in plasma 283 and CSF, was found tolerable in severely ill TBM patients, and showed a trend for reduced mortality among 
288
The strengths of our study are the double-blinding that we applied and the high proportion of bacteriological-289 confirmed TBM cases (71%). Our study also has limitations. First, the sample size was limited, inherent to the 290 study's phase II characteristics and objectives, and the study was not powered to compare the efficacy of the 291 three doses of oral rifampicin. As a result, the apparent mortality benefits of high dose oral rifampicin should be 292 interpreted with caution. Second, we could only take single CSF samples for pharmacokinetic purposes, which 293 means that no pharmacokinetic curves could be generated for CSF.
294
In summary, tripling the dose of oral rifampicin to 30 mg/kg resulted in an increased exposure to rifampicin, 295 both in plasma and CSF, which was not associated with an increase in the incidence of grade 3 and 4 adverse 296 events. The higher 30 mg/kg rifampicin dose resulted in an increase in pharmacokinetic target attainment. In 297 terms of efficacy, further investigation in a larger population is needed to confirm our findings. 
